Section Arrow
LUNG.NASDAQ
- Pulmonx Corp
Quotes are at least 15-min delayed:2026/11/20 17:54 EST
After Hours
Last
 2.7
+0.13 (+5.06%)
Bid
2.5
Ask
2.9
High 2.7 
Low 2.57 
Volume 37.03K 
Regular Hours (Closed)
Last
 2.57
-0.17 (-6.20%)
Day High 
2.805 
Prev. Close
2.74 
1-M High
3.25 
Volume 
933.29K 
Bid
2.5
Ask
2.9
Day Low
2.51 
Open
2.71 
1-M Low
1.75 
Market Cap 
119.33M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.8 
20-SMA 2.66 
50-SMA 2.19 
52-W High 3.25 
52-W Low 1.13 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.01/-0.94
Enterprise Value
174.38M
Balance Sheet
Book Value Per Share
0.79
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
90.50M
Operating Revenue Per Share
1.49
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BSXBoston Scientific Corp41.98-1.01-2.35%18.14PE
After Hours 42.3233 +0.3433 +0.82%
PACBPacific Biosciences of California1.63-0.13-7.39%-- 
After Hours 1.65 +0.02 +1.23%
MDTMedtronic plc99.94-0.67-0.67%24.78PE
After Hours 99.52 -0.42 -0.42%
QSIQuantum-Si0.909-0.161-15.05%-- 
After Hours 0.96 +0.051 +5.61%
ABTAbbott Laboratories103-0.87-0.84%38.76PE
After Hours 103.53 +0.53 +0.51%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic andeither do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.